Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

Search
Advanced Search
OPEN ACCESS
mobile search button mobile menu button

Articles

Page Path
HOME > Cancer Res Treat > Volume 47(2); 2015 > Article
Letter to the Editor Reply to Commentary on “Clinical Characteristics and Adequate Treatment of Familial Adenomatous Polyposis Combined with Desmoid Tumors”
Jin Cheon Kim, MD
Cancer Research and Treatment : Official Journal of Korean Cancer Association 2015;47(2):341-341.
DOI: https://doi.org/10.4143/crt.2015.050
Published online: February 26, 2015

Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Correspondence: Jin Cheon Kim, MD  Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Korea 
Tel: 82-2-3010-3489, Fax: 82-2-474-9027, E-mail: jckim@amc.seoul.kr
• Received: February 10, 2015   • Accepted: February 22, 2015

Copyright © 2015 by the Korean Cancer Association

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

  • 8,728 Views
  • 62 Download
prev
Full Article

Download PDF Download PDF

See the letter "Commentary on “Clinical Characteristics and Adequate Treatment of Familial Adenomatous Polyposis Combined with Desmoid Tumors”" on page 339.
Virgilio et al. [1] reported a case with familial adenomatosis coli (FAP)-related giant desmoid tumors (DTs) of the mesentery following proctocolectomy, and I mostly agree with the authors’inoperable mortality. They reported a 28-year-old female with FAP and DTs abruptly aggravated to death at 6 months postoperatively which was probably related with extensive DTs. Similarly, mesenteric DTs were the main cause of death in FAP patients with DTs, whereas recurrent cancers were the main cause of death in those without DTs, in our previous study [2]. The patient seems to carry three potential risk factors for DTs including female, APC mutation site 3′ to 1440, and previous history of surgery [3]. Herein, the current case gives us an important lesson for careful attention about possible DTs during operation and immediately after proctocolectomy, particularly in FAP patients with risk factors. Although the response might be unpredictable for complicated DTs, non-surgical treatment options would be immediately provided if any symptoms or signs were identified during early postoperative period. For the extensive DTs, nonsurgical treatment optionsincluding radiotherapy,systemic chemotherapy including doxorubicin plus dacarbazine, biologicssuch asimatinib, non-steroidal anti-inflammatory agents, and anti-hormonal agents, have been provided to yield variable responses. Among these options, anti-estrogen agents, alone or in combination with nonsteroidal anti-inflammatory drugs, were identified with an overall response rate of 51% according to a systematic analysis using a total of 168 DTs [4]. We have experienced estrogen receptor antagonist combined with or without luteinizing hormone releasing hormone agonist to stabilize extensive mesenteric DTs. In a total of 10 FAP patients accompanying extensive mesenteric DTs which were not completely resected, seven patients have been alive well leading ordinary lifestyles for 17-133 months (median, 101 months) after diagnosis, showing partial response or stable disease to tamoxifen with or without goserelin acetate. On the other hand, several groups presently reported the graft preservation rate after multi-visceral transplantation as approximately 50% in patients with extensive abdominal DTs [5]. Although bowel transplantation is considered as a life-saving procedure, knotty subjects must be preferentially verified to be an established practice, i.e., severe morbidity, high graft failure and mortality, recurrent DTs, and accessibility. Conclusively, further studies including surgical and non-surgical modalities treating FAP patients with extensive DTs are needed to consolidate the evidence for the efficiency and safety of respective regimen.

Conflict of interest relevant to this article was not reported.

  • 1. Virgilio E, Di Gregorio F, Balducci G. Commentary on “clinical characteristics and adequate treatment of familial adenomatous polyposis combined with desmoid tumors”. Cancer Res Treat. 2015 Feb 26 [Epub]. http://dx.doi.org/10.4143/crt.2015.038ArticlePubMedPMCPDF
  • 2. Jung WB, Kim CW, Kim JC. Clinical characteristics and adequate treatment of familial adenomatous polyposis combined with desmoid tumors. Cancer Res Treat. 2014;46:366–73. ArticlePubMedPMCPDF
  • 3. Vitellaro M, Sala P, Signoroni S, Radice P, Fortuzzi S, Civelli EM, et al. Risk of desmoid tumours after open and laparoscopic colectomy in patients with familial adenomatous polyposis. Br J Surg. 2014;101:558–65. ArticlePubMed
  • 4. Bocale D, Rotelli MT, Cavallini A, Altomare DF. Anti-oestrogen therapy in the treatment of desmoid tumours: a systematic review. Colorectal Dis. 2011;13:e388–95. ArticlePubMed
  • 5. Moon JI, Selvaggi G, Nishida S, Levi DM, Kato T, Ruiz P, et al. Intestinal transplantation for the treatment of neoplastic disease. J Surg Oncol. 2005;92:284–91. ArticlePubMed

Figure & Data

REFERENCES

    Citations

    Citations to this article as recorded by  

      • PubReader PubReader
      • ePub LinkePub Link
      • Cite
        CITE
        export Copy Download
        Close
        Download Citation
        Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.
        Format:
        • RIS — For EndNote, ProCite, RefWorks, and most other reference management software
        • BibTeX — For JabRef, BibDesk, and other BibTeX-specific software
        Include:
        • Citation for the content below
        Reply to Commentary on “Clinical Characteristics and Adequate Treatment of Familial Adenomatous Polyposis Combined with Desmoid Tumors”
        Cancer Res Treat. 2015;47(2):341-341.   Published online February 26, 2015
        DOI: https://doi.org/10.4143/crt.2015.050
        Close
      • XML DownloadXML Download
      Reply to Commentary on “Clinical Characteristics and Adequate Treatment of Familial Adenomatous Polyposis Combined with Desmoid Tumors”
      Reply to Commentary on “Clinical Characteristics and Adequate Treatment of Familial Adenomatous Polyposis Combined with Desmoid Tumors”
      Cancer Res Treat : Cancer Research and Treatment
      © Korean Cancer Association.
      Close layer
      TOP